PF-Atlas › Clinical Trials › NCT02370693
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
Bortezomib · Phase 2
Registry ID
NCT02370693
Phase
Phase 2
Status
Completed
Drug / intervention
Bortezomib
Sponsor
Northwestern University
Start
2016-03
Enrollment
9
Locations
1
About this trial
The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02370693 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.